Detalhe da pesquisa
1.
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.
Eur Heart J
; 41(40): 3936-3945, 2020 10 21.
Artigo
Inglês
| MEDLINE | ID: mdl-32860031
2.
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia.
N Engl J Med
; 373(5): 438-47, 2015 Jul 30.
Artigo
Inglês
| MEDLINE | ID: mdl-26222559
3.
Targeting APOC3 in the familial chylomicronemia syndrome.
N Engl J Med
; 371(23): 2200-6, 2014 Dec 04.
Artigo
Inglês
| MEDLINE | ID: mdl-25470695
4.
Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.
Lancet
; 386(10002): 1472-83, 2015 Oct 10.
Artigo
Inglês
| MEDLINE | ID: mdl-26210642
5.
No effect on QT intervals of mipomersen, a 2'-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects.
Eur J Clin Pharmacol
; 72(3): 267-75, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26645588
6.
Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Circ Res
; 112(11): 1479-90, 2013 May 24.
Artigo
Inglês
| MEDLINE | ID: mdl-23542898
7.
Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial.
Ann Neurol
; 66(1): 28-38, 2009 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-19670432
8.
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.
Diabetes Care
; 39(8): 1408-15, 2016 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-27271183
9.
Results of a proof of concept, double-blind, randomized trial of a second generation antisense oligonucleotide targeting high-sensitivity C-reactive protein (hs-CRP) in rheumatoid arthritis.
Arthritis Res Ther
; 17: 80, 2015 Mar 19.
Artigo
Inglês
| MEDLINE | ID: mdl-25885521
10.
A Selective Inhibitor of Human C-reactive Protein Translation Is Efficacious In Vitro and in C-reactive Protein Transgenic Mice and Humans.
Mol Ther Nucleic Acids
; 1: e52, 2012 Nov 13.
Artigo
Inglês
| MEDLINE | ID: mdl-23629027